Publications
- Persistent Overall Survival Benefit and No Increased Risk of Second Malignancies With Bortezomib-Melphalan-Prednisone Versus Melphalan-Prednisone in Patients With Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma2013 | First Faculty of Medicine
- Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma2013 | First Faculty of Medicine
- Intrapleural Bortezomib for the Therapy of Myelomatous Pleural Effusion: A Case Report2012 | First Faculty of Medicine
- Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma2011 | First Faculty of Medicine
- Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed multiple myeloma patients: subanalysis of the phase 3 VISTA study2011 | First Faculty of Medicine
- An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation2011 | First Faculty of Medicine
- Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial2010 | First Faculty of Medicine
- Bortezomid in the first line therapy2009 | First Faculty of Medicine
- Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.2008 | First Faculty of Medicine
Loading network view...